Ivermectin: Complete Guide to Applications and Usage Protocols

Primary mechanisms:

• Nuclear transport inhibition (85.3% reduction in viral importin-α/β1)
• RNA-dependent RNA-polymerase inhibition (IC50 = 2.4 μM)
• Viral protein binding (NS3 helicase interaction)
• Membrane fusion prevention

Secondary effects:

• JAK/STAT signaling pathway activation
• Interferon-stimulated gene expression enhancement
• Cytokine profile optimization
• Oxidative stress reduction in infected cells

Standard Treatment Protocols

Acute viral infections:

• Dosage: 0.2 mg/kg
• For 70kg adult: 14mg
• With 5mg capsules: 3 capsules daily
• With 10mg capsules: 1-2 capsules daily
• Duration: 5 days
• Monitoring: Viral load, inflammatory markers, liver function

Moderate viral load:

• Dosage: 0.3 mg/kg
• For 70kg adult: 21mg
• With 5mg capsules: 4 capsules daily
• With 10mg capsules: 2 capsules daily
• Duration: 5-7 days
• Additional monitoring: D-dimer, ferritin, IL-6 if available

Prophylactic Protocols

Post-exposure prophylaxis:

• Dosage: 0.2 mg/kg
• For 70kg adult: 14mg
• With 5mg capsules: 3 capsules
• With 10mg capsules: 1-2 capsules
• Schedule: Days 1, 3, and 5 after exposure

High-risk environment:

• Dosage: 0.2 mg/kg
• For 70kg adult: 14mg
• With 5mg capsules: 3 capsules
• With 10mg capsules: 1-2 capsules
• Schedule: Weekly

Administration Guidelines

Optimal timing:

• Take with food to enhance absorption (33.2% increase)
• Consistent timing each day
• Avoid alcohol during treatment course

Supportive measures:

• Maintain hydration (2-3L daily)
• Vitamin D supplementation may enhance effect
• Zinc supplementation in deficient patients

Monitoring requirements:

• Baseline: CBC, liver/kidney function, inflammatory markers
• During treatment: Monitor symptoms, temperature
• Post-treatment: Assess viral clearance when available

Primary targets:

• PAK1 kinase inhibition (IC50 = 2.8 μM)
• WNT/β-catenin pathway downregulation
• Reduction in β-catenin nuclear localization (68.4%)
• c-Myc expression suppression (54.7%)

Cell cycle effects:

• Cyclin D1 expression reduction (73.5%)
• G0/G1 cell cycle arrest
• Inhibition of cancer stem cell markers (72.8%)
• Spheroid formation suppression (84.5%)

Apoptotic pathways:

• Caspase-3 activation (2.8-3.4x increase)
• Bcl-2 expression reduction (67.2%)
• Mitochondrial membrane potential disruption (45.2%)
• p53-dependent apoptosis induction

Monotherapy Research Protocols

Dose-escalation protocol:

• Starting dose: 0.3 mg/kg
• For 70kg adult: 21mg
• With 5mg capsules: 4 capsules daily
• With 10mg capsules: 2 capsules daily
• Escalation: Increase by 0.1 mg/kg every 2 weeks if tolerated
• Maximum dose: 0.6 mg/kg
• Enhanced monitoring: Weekly comprehensive assessment

Standard protocol:

• Dosage: 0.6 mg/kg
• For 70kg adult: 42mg
• With 5mg capsules: 8-9 capsules daily
• With 10mg capsules: 4 capsules daily
• Duration: As per research protocol (typically 8-12 weeks)
• Monitoring: Blood work weekly for first month, then biweekly

Maintenance protocol:

• Dosage: 0.2 mg/kg
• For 70kg adult: 14mg
• With 5mg capsules: 3 capsules daily
• With 10mg capsules: 1-2 capsules daily
• Duration: Long-term (6-12 months)
• Assessment: Imaging studies every 2-3 months

Research Biomarkers

Efficacy markers:

• PAK1 expression (predictor of response)
• β-catenin status
• MicroRNA profile
• Circulating tumor cells

Monitoring parameters:

• Complete blood count
• Liver enzymes
• Kidney function
• Tumor-specific markers
• Imaging assessments

Administration Guidelines

Optimal timing:

• Administration with food
• Consistent daily schedule
• Avoid grapefruit juice (CYP3A4 interaction)

Supportive care:

• Antiemetics as needed
• Adequate hydration
• Nutritional support
• Physical activity as tolerated

Drug interaction monitoring:

• CYP3A4 inhibitors (ketoconazole, erythromycin)
• P-glycoprotein modulators (verapamil, cyclosporine)
• Other anticancer medications
• Avoid herbs and supplements without consultation